2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Alzheimer Disease D000544 76 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Body Weight D001835 333 associated lipids
Brain Concussion D001924 5 associated lipids
Brain Edema D001929 20 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Catalepsy D002375 30 associated lipids
Brain Ischemia D002545 89 associated lipids
Colitis D003092 69 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Encephalitis D004660 15 associated lipids
Epilepsy D004827 35 associated lipids
Fatty Liver, Alcoholic D005235 11 associated lipids
Fragile X Syndrome D005600 5 associated lipids
Glioma D005910 112 associated lipids
Hepatic Encephalopathy D006501 9 associated lipids
Hyperalgesia D006930 42 associated lipids
Hyperinsulinism D006946 27 associated lipids
Hyperkinesis D006948 11 associated lipids
Hypotension D007022 41 associated lipids
Hypothermia D007035 19 associated lipids
Inflammation D007249 119 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Memory Disorders D008569 33 associated lipids
Morphine Dependence D009021 9 associated lipids
Nerve Degeneration D009410 53 associated lipids
Nervous System Diseases D009422 37 associated lipids
Neuralgia D009437 28 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Obesity D009765 29 associated lipids
Pain D010146 64 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Starvation D013217 47 associated lipids
Stomach Ulcer D013276 75 associated lipids
Reperfusion Injury D015427 65 associated lipids
Myocardial Reperfusion Injury D015428 20 associated lipids
Weight Gain D015430 101 associated lipids
Head Injuries, Closed D016489 5 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Ganglion Cysts D045888 1 associated lipids
Fetal Nutrition Disorders D048070 1 associated lipids
Acute Lung Injury D055371 33 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Turunen PM et al. Endocannabinoid Signaling in Embryonic Neuronal Motility and Cell-Cell Contact - Role of mGluR5 and TRPC3 Channels. 2018 Neuroscience pmid:29438802
Roberts CJ et al. Swim stress differentially affects limbic contents of 2-arachidonoylglycerol and 2-oleoylglycerol. 2012 Neuroscience pmid:22192839
Ludányi A et al. Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. 2011 Neuroscience pmid:21035522
Ikeda H et al. Activation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice. 2013 Neuroscience pmid:23892011
Hutch CR et al. An endocannabinoid system is present in the mouse olfactory epithelium but does not modulate olfaction. 2015 Neuroscience pmid:26037800
Gopez JJ et al. Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. 2005 Neurosurgery pmid:15730585
Smaga I et al. Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures. 2014 Neurotox Res pmid:24652522
Smaga I et al. Changes in the Brain Endocannabinoid System in Rat Models of Depression. 2017 Neurotox Res pmid:28247204
Carr RL et al. Decreased anxiety in juvenile rats following exposure to low levels of chlorpyrifos during development. 2017 Neurotoxicology pmid:26642910
Rademacher DJ et al. Waterborne lead exposure affects brain endocannabinoid content in male but not female fathead minnows (Pimephales promelas). 2005 Neurotoxicology pmid:15527869
Liu J et al. Comparative effects of parathion and chlorpyrifos on endocannabinoid and endocannabinoid-like lipid metabolites in rat striatum. 2015 Neurotoxicology pmid:26215119
Tsuyama S et al. Dietary conjugated linoleic acid modifies the brain endocannabinoid system in mice. 2009 Nutr Neurosci pmid:19622239
Haas MJ et al. Inhibition of apolipoprotein A-I gene expression by obesity-associated endocannabinoids. 2012 Obesity (Silver Spring) pmid:22016100
Gonthier MP et al. Identification of endocannabinoids and related compounds in human fat cells. 2007 Obesity (Silver Spring) pmid:17426318
Starowicz KM et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. 2008 Obesity (Silver Spring) pmid:18239598
Zelber-Sagi S et al. Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease. 2017 Obesity (Silver Spring) pmid:27863097
Abdulnour J et al. Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study. 2014 Obesity (Silver Spring) pmid:23616305
Engeli S et al. Peripheral endocannabinoid system activity in patients treated with sibutramine. 2008 Obesity (Silver Spring) pmid:18356837
Motaghedi R and McGraw TE The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. 2008 Obesity (Silver Spring) pmid:18551116
Bernabò N et al. Systems biology analysis of the endocannabinoid system reveals a scale-free network with distinct roles for anandamide and 2-arachidonoylglycerol. 2013 OMICS pmid:24117401
Echigo R et al. Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-κB and cell growth in U87MG human malignant glioma cells. 2012 Oncol. Rep. pmid:22842590
Orellana-Serradell O et al. Proapoptotic effect of endocannabinoids in prostate cancer cells. 2015 Oncol. Rep. pmid:25606819
Vujic N et al. Monoglyceride lipase deficiency affects hepatic cholesterol metabolism and lipid-dependent gut transit in ApoE-/- mice. 2017 Oncotarget pmid:28380440
Rea K et al. Evidence for a role of GABAergic and glutamatergic signalling in the basolateral amygdala in endocannabinoid-mediated fear-conditioned analgesia in rats. 2013 Pain pmid:23414578
Telleria-Diaz A et al. Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids. 2010 Pain pmid:19879047
Bradshaw H CB1-induced side effects of specific COX-2 inhibitors: a feature, not a bug. 2010 Pain pmid:19913999
La Porta C et al. Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. 2015 Pain pmid:26067584
Carloni S et al. Pretreatment with the monoacylglycerol lipase inhibitor URB602 protects from the long-term consequences of neonatal hypoxic-ischemic brain injury in rats. 2012 Pediatr. Res. pmid:22821058
den Boon FS et al. Endocannabinoids produced upon action potential firing evoke a Cl(-) current via type-2 cannabinoid receptors in the medial prefrontal cortex. 2014 Pflugers Arch. pmid:24671573
Carrasquer A et al. Functional consequences of nonsynonymous single nucleotide polymorphisms in the CB2 cannabinoid receptor. 2010 Pharmacogenet. Genomics pmid:20124950
Pérez-Morales M et al. 2-AG into the lateral hypothalamus increases REM sleep and cFos expression in melanin concentrating hormone neurons in rats. 2013 Pharmacol. Biochem. Behav. pmid:23603032
Wakley AA and Rasmussen EB Effects of cannabinoid drugs on the reinforcing properties of food in gestationally undernourished rats. 2009 Pharmacol. Biochem. Behav. pmid:19602424
Stanley CP and O'Sullivan SE Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries. 2014 Pharmacol. Res. pmid:24548820
Eisenstein SA et al. A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy. 2010 Pharmacol. Res. pmid:20044005
Deshmukh RR and Sharma PL Stimulation of accumbens shell cannabinoid CB(1) receptors by noladin ether, a putative endocannabinoid, modulates food intake and dietary selection in rats. 2012 Pharmacol. Res. pmid:22728691
Khasabova IA et al. JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy. 2014 Pharmacol. Res. pmid:25304184
Navarria A et al. The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. 2014 Pharmacol. Res. pmid:24861565
Spradley JM et al. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. 2010 Pharmacol. Res. pmid:20416378
Leishman E et al. Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain. 2016 Pharmacol. Res. pmid:27109320
Guindon J et al. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. 2013 Pharmacol. Res. pmid:23127915
Sciolino NR et al. Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. 2011 Pharmacol. Res. pmid:21600985
Stefano GB et al. 2-arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. 2000 Pharmacol. Res. pmid:10987990
Malek N et al. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain. 2016 Pharmacol. Res. pmid:27326920
Fowler CJ and Ghafouri N Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake? 2008 Pharmacol. Res. pmid:18675915
Nicolussi S et al. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice. 2014 Pharmacol. Res. pmid:24412246
Khasabova IA et al. Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. 2011 Pharmacol. Res. pmid:21440630
Bakas T et al. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA receptors. 2017 Pharmacol. Res. pmid:28249817
Pagano E et al. Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis. 2017 Pharmacol. Res. pmid:28193521
Straiker A et al. Aiming for allosterism: Evaluation of allosteric modulators of CB1 in a neuronal model. 2015 Pharmacol. Res. pmid:26211948
Imperatore R et al. Formation of OX-1R/CB1R heteromeric complexes in embryonic mouse hypothalamic cells: Effect on intracellular calcium, 2-arachidonoyl-glycerol biosynthesis and ERK phosphorylation. 2016 Pharmacol. Res. pmid:27436148